Jump to main content
Jump to site search


The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease

Abstract

This study was performed to investigate the effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD). This randomized, double-blind, placebo-controlled trial was performed in 56 patients with T2DM and CHD. Patients were randomly divided into two groups to receive either 500 mg resveratrol/day (n=28) or placebo (n=28) for 4 weeks. Resveratrol reduced fasting glucose (β -10.04 mg/dL; 95% CI, -18.23, -1.86; P=0.01), insulin (β -1.09 µIU/mL; 95% CI, -1.93, -0.24; P=0.01) and insulin resistance (β -0.48; 95% CI, -0.76, -0.21; P=0.001), and significantly increased insulin sensitivity (β 0.006; 95% CI, 0.001, 0.01; P=0.02) when compared with the placebo. Resveratrol also significantly increased HDL-cholesterol levels (β 3.38 mg/dL; 95% CI, 1.72, 5.05; P<0.001) and significantly decreased total-/HDL-cholesterol ratio (β -0.36; 95% CI, -0.59, -0.13; P=0.002) when compared with the placebo. Additionally, resveratrol caused a significant increase in total antioxidant capacity (TAC) (β 58.88 mmol/L; 95% CI, 17.33, 100.44; P=0.006) and a significant reduction in malondialdehyde (MDA) levels (β -0.21 µmol/L; 95% CI, -0.41, -0.005; P=0.04) when compared with the placebo. Resveratrol upregulated PPAR-γ (P=0.01) and sirtuin 1 (SIRT1) (P=0.01) in peripheral blood mononuclear cell (PBMC) of T2DM patients with CHD. Resveratrol supplementation did not have any effect on inflammatory markers. 4-week supplementation with resveratrol in patients with T2DM and CHD had beneficial effects on glycemic control, HDL-cholesterol, total-/HDL-cholesterol ratio, TAC and MDA levels. Resveratrol also upregulated PPAR-γ and SIRT1 in PBMC of T2DM patients with CHD.

Back to tab navigation

Supplementary files

Publication details

The article was received on 20 May 2019, accepted on 07 Aug 2019 and first published on 08 Aug 2019


Article type: Paper
DOI: 10.1039/C9FO01075K
Food Funct., 2019, Accepted Manuscript

  •   Request permissions

    The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease

    A. Hoseini, G. Namazi, A. Farrokhian, Ž. Reiner , E. Aghadavod, F. Bahmani and Z. Asemi, Food Funct., 2019, Accepted Manuscript , DOI: 10.1039/C9FO01075K

Search articles by author

Spotlight

Advertisements